Clinical trial
Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)
NCT00478699 · Spanish Lung Cancer Group, Other · Completed
Key facts
| NCT number | NCT00478699 |
|---|---|
| Title | Randomized Customized Adjuvant Chemotherapy (GECP-SCAT) |
| Official title | Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients |
| Acronym | GECP-SCAT |
| Lead sponsor | Spanish Lung Cancer Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-small-cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel/Cisplatin control, Docetaxel, Gemcitabine/Cisplatin, Docetaxel/Cisplatin |
| Enrollment | 500 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | May 25, 2007 |
| Last update posted | Dec 12, 2024 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: